Traditional Chinese medicine for myocardial infarction: an overview.

OBJECTIVES: This overreview aimed to evaluate the methodological quality and reporting quality of the systematic reviews of Chinese herbal medicine. METHODS: Electronic literature databases, including the PubMed, Embase, Cochrane library two Chinese databases (China National Knowledge Internet and Wanfang database) from inception to November 2011 were searched. Systematic reviews and Meta-analyses of the Chinese medicine for myocardial infarction were included. Data were extracted by two independent reviewers. AMSTAR (Assessment of Multiple Systematic Reviews) and PRIMSMA Preferred Reporting Items for Systematic Reviews and Meta-Analysis were used to assess the methodological and reporting quality of the included systematic reviews. RESULTS: Ten reviews were included. One SR was concerned with ventricular remodelling after myocardial infarction, one was concerned with hypotension after myocardial infarction, and the rest related to the myocardial infarction. The interpretation of the included systematic reviews was poor. CONCLUSIONS: A number of systematic reviews have become available, but the therapeutic value of traditional Chinese medicine remains limited.

High-throughput identification of autoantibodies that target the human exoproteome.

Autoantibodies that recognize extracellular proteins (the exoproteome) exert potent biological effects but are challenging to detect. Here, we developed rapid extracellular antigen profiling (REAP), a high-throughput technique for the comprehensive discovery of exoproteome-targeting autoantibodies. Patient samples are applied to a genetically barcoded yeast surface display library containing 2,688 human extracellular proteins. Antibody-coated yeast are isolated, and sequencing of barcodes is used to identify displayed antigens. To benchmark REAP's performance, we screened 77 patients with autoimmune polyglandular syndrome type 1 (APS-1). REAP sensitively and specifically detected both known and previously unidentified autoantibodies in APS-1. We further screened 106 patients with systemic lupus erythematosus (SLE) and identified numerous autoantibodies, several of which were associated with disease severity or specific clinical manifestations and exerted functional effects on cell signaling ex vivo. These findings demonstrate the utility of REAP to atlas the expansive landscape of exoproteome-targeting autoantibodies and their impacts on patient health outcomes.